# Dose Optimized BNCT for Head and Neck Cancer

> **NCT05883007** · PHASE1 · UNKNOWN · sponsor: **Southern Tohoku BNCT Research Center** · enrollment: 30 (estimated)

## Conditions studied

- Head and Neck Cancer
- Squamous Cell Carcinoma

## Interventions

- **RADIATION:** Accelerator-based BNCT with borofalan(10B)

## Key facts

- **NCT ID:** NCT05883007
- **Lead sponsor:** Southern Tohoku BNCT Research Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-06-01
- **Primary completion:** 2022-05-31
- **Final completion:** 2024-05-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2023-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05883007

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05883007, "Dose Optimized BNCT for Head and Neck Cancer". Retrieved via AI Analytics 2026-09-03 from https://api.ai-analytics.org/clinical/NCT05883007. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*